Vildagliptin STADA 50 mg tabletti 핀란드 - 핀란드어 - Fimea (Suomen lääkevirasto)

vildagliptin stada 50 mg tabletti

stada arzneimittel ag - vildagliptin - tabletti - 50 mg - vildagliptiini

Icandra (previously Vildagliptin / metformin hydrochloride Novartis) 유럽 연합 - 핀란드어 - EMA (European Medicines Agency)

icandra (previously vildagliptin / metformin hydrochloride novartis)

novartis europharm limited - vildagliptiini, metformiinihydrokloridia - diabetes mellitus, tyyppi 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 ja 5. 1 käytettävissä olevista tiedoista eri yhdistelmistä).

Zomarist 유럽 연합 - 핀란드어 - EMA (European Medicines Agency)

zomarist

novartis europharm limited  - vildagliptiini, metformiinihydrokloridia - diabetes mellitus, tyyppi 2 - diabeetilla käytettävät lääkkeet - zomarist is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate.

Eucreas 유럽 연합 - 핀란드어 - EMA (European Medicines Agency)

eucreas

novartis europharm limited - vildagliptiini, metformiinihydrokloridia - diabetes mellitus, tyyppi 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - eucreas is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

Galvus 유럽 연합 - 핀란드어 - EMA (European Medicines Agency)

galvus

novartis europharm limited - vildagliptiini - diabetes mellitus, tyyppi 2 - diabeetilla käytettävät lääkkeet - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

Jalra 유럽 연합 - 핀란드어 - EMA (European Medicines Agency)

jalra

novartis europharm limited - vildagliptiini - diabetes mellitus, tyyppi 2 - dipeptidyl peptidase 4 (dpp-4) inhibitors, drugs used in diabetes - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 ja 5. 1 käytettävissä olevista tiedoista eri yhdistelmistä).

Xiliarx 유럽 연합 - 핀란드어 - EMA (European Medicines Agency)

xiliarx

novartis europharm limited - vildagliptiini - diabetes mellitus, tyyppi 2 - diabeetilla käytettävät lääkkeet - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 ja 5. 1 käytettävissä olevista tiedoista eri yhdistelmistä).

Renitec 5 mg tabletti 핀란드 - 핀란드어 - Fimea (Suomen lääkevirasto)

renitec 5 mg tabletti

n.v. organon - enalapril maleate - tabletti - 5 mg - enalapriili

Renitec 20 mg tabletti 핀란드 - 핀란드어 - Fimea (Suomen lääkevirasto)

renitec 20 mg tabletti

n.v. organon - enalapril maleate - tabletti - 20 mg - enalapriili